A Randomized Phase III Comparison of Standard- Dose (60 Gy) Versus Highdose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer
Principal Investigator
Jeffrey Bradley, MD
Status
Terminated
Date Opened To Accrual
November 27 2007
Date Closed to Accrual
November 22 2011
Date of Study Termination
May 20 2022
Disease Site
Lung [LU]
Non-small Cell Lung Cancer
Phase
III
Developmental Therapeutics
No
Primary Objective
To compare the overall survival of patients treated with high-dose versus standard-dose conformal radiation therapy in the setting of concurrent chemotherapy; To compare the overall survival of patients treated with cetuximab versus without cetuximab in the setting of concurrent chemotherapy.
NOTE: See broadcast regarding paclitaxel shortage and RTOG 0617 recommended modifications (broadcast on 9/23/11 and posted to web site on 10/26/11).
Patient Population
Newly diagnosed unresectable Stage III A or B non-small cell lung cancer (NSCLC); patients who present with N2 or N3 disease and an undetectable NSCLC primary tumor also are eligible; patients with supraclavicular or contralateral hilar adenopathy are ineligible.
Target Accrual
500
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.